GSK plc GLAXF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -75.05% | 176.67% | -68.84% | 40.81% | -5.76% |
| Total Depreciation and Amortization | -52.01% | 174.92% | -183.66% | 20.35% | -20.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6,276.90% | -98.58% | 4,250.14% | -103.70% | 319.76% |
| Change in Net Operating Assets | 151.57% | -369.31% | 181.93% | 52.03% | -38.77% |
| Cash from Operations | 134.91% | -49.26% | 1.12% | 7.01% | 94.15% |
| Capital Expenditure | -47.88% | 60.93% | -81.72% | -22.63% | -30.54% |
| Sale of Property, Plant, and Equipment | -88.93% | 110.40% | 156.45% | 0.94% | 430.31% |
| Cash Acquisitions | 51.67% | -3,217.04% | 95.07% | -28,836.49% | 99.60% |
| Divestitures | -93.90% | 24,718.26% | -1.36% | 103.61% | -2,869.69% |
| Other Investing Activities | 286.48% | 66.64% | 10.80% | -7.71% | -173.53% |
| Cash from Investing | 46.37% | -59.17% | 39.89% | -147.27% | 42.05% |
| Total Debt Issued | -77.29% | 117.75% | 790.00% | -112.40% | -68.95% |
| Total Debt Repaid | -1,212.33% | 7.59% | -27.42% | 96.06% | -627.78% |
| Issuance of Common Stock | -87.50% | 700.00% | -- | -100.00% | -83.33% |
| Repurchase of Common Stock | 5.52% | -29.37% | 20.50% | 43.49% | -127.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -12.66% | -0.83% | 1.97% | -0.02% | -13.69% |
| Other Financing Activities | -513.46% | 124.07% | -109.71% | 10.43% | -47.44% |
| Cash from Financing | -887.22% | 132.19% | 35.80% | 44.04% | -393.22% |
| Foreign Exchange rate Adjustments | -448.73% | 104.94% | -168.54% | 329.06% | -150.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -314.19% | -111.53% | 178.21% | 38.48% | -215.94% |